Abstract
We applaud the study by Rosalind Parkes-Ratanshi and colleagues,1 which showed the development of cryptococcal disease among patients with HIV/AIDS who were initially cryptococcal antigen (CrAg) negative, and the benefit of primary fluconazole prophylaxis in this population. Our group and others in South Africa have supported efforts to increase screening and treatment of severely immunocompromised HIV-infected people for CrAg by reflexive testing with a new rapid and simple US Food and Drug Administration cleared lateral flow assay (LFA) among patients with a CD4 count of less than 100 cells per μL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
